www.pharmavoice.com

SPECIAL ISSUE

���

� � �� �� � �� �� � �� �� � �� �

� � �� �� � �� �

SILAICEPS

� � �� �� � �� �

EUSS

NOITACILBUP

Their Word...

PUBLISHER Lisa BanketEDITOR Taren Grom

CREATIVE DIRECTOR Marah Walsh

MANAGING EDITORDenise MyshkoSENIOR EDITORRobin Robinson

FEATURES EDITORKim Ribbink

CONTRIBUTING EDITOR Carolyn Gretton

DESIGN ASSOCIATEAriel Medel

NATIONAL ACCOUNT MANAGERSTrish KaneCathy Tracy

WEBCAST NETWORK PRODUCERDaniel Limbach

CIRCULATION ASSISTANTKathy Deiuliis

Copyright 2011by PharmaLinx LLC, Titusville, NJ

Printed in the U.S.A.Volume Eleven, Number Seven

PharmaVOICE (ISSN: 1932961X) is published monthly ex-cept joint issues in July/Aug. and Nov./Dec., by Pharma LinxLLC, P.O. Box 327, Titusville, NJ 08560. Periodicals postagepaid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVOICE,P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVOICE Coverage and Distribution:Domestic subscriptions are available at $190 for oneyear (10 issues). Foreign subscriptions: 10 issuesUS$360. Contact PharmaVOICE at P.O. Box 327, Ti-tusville, NJ 08560. Call us at 609.730.0196 or FAX yourorder to 609.730.0197.

Contributions: PharmaVOICE is not responsible for un-solicited contributions of any type. Unless otherwiseagreed in writing, PharmaVOICE retains all rights on ma-terial published in PharmaVOICE for a period of sixmonths after publication and reprint rights after that pe-riod expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a changeof address. Send your new address along with your sub-scription label to PharmaVOICE, P.O. Box 292345, Kettering,OH 45429-0345. Call us at 800.607.4410 or FAX your changeto 937.890.0221. E-mail: mwalsh@pharmavoice.com.

IMPORTANT NOTICE: The post office will not forwardcopies of this magazine. PharmaVOICE is not respon-sible for replacing undelivered copies due to lack of orlate notification of address change.

Advertising in PharmaVOICE: To advertise in Pharma - VOICE please contact our Advertising Department atP.O. Box 327, Titusville, NJ 08560, or telephone us at609.730.0196. E-mail: lbanket@pharmavoice.com.

Send your letters to feedback@pharma voice.com.Please include your name, title, company, and busi-ness phone number. Letters chosen for publicationmay be edited for length and clarity. All submissionsbecome the property of PharmaLinx LLC.

Letters...

Printed on recycled paper

tgrom@pharmavoice.com

Taren GromEditor

THE FORUM FOR THE INDUSTRY EXECUTIVE

Regards,

Letter from the Editor

Taking Inspirationto the Next LevelTHIS IS OUR FAVORITE ISSUE OF THE YEAR, AND WE HOPE IT’S YOURSTOO. It has been a joy and a privilege to have had a chance to get to knowthis year’s PharmaVOICE 100. They certainly illustrate what it means tothink bigger, do more, and lead with passion and integrity. It’s no surprisethat you, our readers, have identified this year’s class as some of the mostinspiring, motivating, and outstanding leaders in the life-sciences industry. This special issue, now in its seventh year, has become one of the

most-anticipated publications of the year. And it is our extreme pleasureto once again showcase these men and women who are providing exem-plary leadership, driving change, innovating in the clinic and the mar-ket, and fostering relationships to position the industry in the best waypossible to serve the ultimate stakeholders: patients.This special publication, which has become known as the feel-good

issue of the year, is packed with in-depth profiles showcasing each leader’sstory. To make the issue easy to navigate, we have divided the honoreesinto categories that we believe best capture their expertise, which is noeasy feat as each of this year’s honorees could easily fit into several of thefollowing sections: commanders and chiefs, entrepreneurs, changeagents, clinical specialists, researchers and scientists, marketers, patientadvocates, and technologists.With thousands of nominations to consider, our editorial team relies

on the personal accounts from our readers that describe why these indi-viduals are special. So we thank all of you who took time out of your busyschedules to nominate the individuals who have made, and continue tomake, a difference in your careers, lives, and organizations. We also wantto thank all of our PharmaVOICE 100 honorees for taking the time toshare their personal stories with us. Please join us in extending warm congratulations to our esteemed

group. I hope you enjoy getting to know them as much as we did;send us your feedback. Don’t forget to check out the exclusive bonuscontent found only in our digital edition, which can be accessed viathe QR code at the end of each profile. We can’t wait to see whomakes next year’s list. Submit your nominations for 2012 now.

DENISE MYSHKO

Managing Editor

I’m inspired by the

commitment this year’s

PharmaVOICE 100

honorees have made to

giving back to their communities.

ROBIN ROBINSON

Senior Editor

When I read the PV 100,

I am humbled by the

number of people in this

industry who get up

every morning with the intent to

make lasting contributions to

healthcare. From science to sales,

molecule to market, they are

adept at making a difference.

KIM RIBBINK

Features Editor

I am inspired by theleaders who step out ofthe comfort of their own successes to help others,however big or small

that contribution.

CAROLYN GRETTON

Contributing Editor

I am truly impressed by

the creativity and

innovation represented

by the PV 100, as well as

their dedication to the people

around them.

Volume 11 • Number 7

COMINGin September>Customer-Centric Segmentation:

Physician/Patient Targeting>Mentoring

> Regenerative Medicine

> Emerging Market — Mexico

> Showcase Feature — Data Management

2 July/August 2011 � PharmaVOICE

Index by Company

Neil WeismanBlue Chip

Healthcare Marketing

David Ormeshercloserlook inc.

Fran HellerExelixis

Dr. Javier RevueltaPérezINC Research

Darlene DobryOgilvy CommonHealth

Medical Marketing

Dr. Uwe TigörPalio

Ahsan AwanPharmaLink

Jeff SweeneyRCW McCann Healthcare

Kurt MuellerRoska Healthcare

Advertising

Mark WillmannTorre Lazur HealthcareGroup

Acorda Therapeutics Andrew Blight, Ph.D.ACT Biotech Inc. Ali Fattaey, Ph.D.Acucela Inc. Ryo Kubota, M.D., Ph.D.Alliance Healthcare

Information LLC Mary Anne GreenbergAlmac Group Sir Allen McClayThe Avoca Group Inc. Patricia LeuchtenAXON US Mario NacinovichBeardsworth Group Donna BeardsworthBenchmark Research Mark LacyBlue Chip Healthcare

Marketing Neil WeismanBristol-Myers Squibb Michael Castagna, Pharm.D.Bristol-Myers Squibb Sarah WharmbyCatabasis Pharmaceuticals Michael Jirousek, Ph.D.Cegedim Compliance

Solutions William BuzzeoCempra Pharmaceuticals Prabhavathi FernandesCenterphase Solutions Inc. Beth HarperCephalon Inc. Frank Baldino Jr., Ph.D.ClearPoint Philip McCreaClinica Responsable

Operativa Marlene Llopiz, M.D.Clinical Practice Insights LLC Tiffany PatrickClinStar David Passovcloserlook inc. David OrmesherCompass IRB LLC Matthew BakerCordis Corp., a J&J company Ryan Saadi, M.D. Core Principle Solutions Pam Rattananont FerrisCryerHealth Donna CryerDudnyk Frank PowersDuke Clinical Research

Institute Elizabeth ReideClinical Solutions Katrina RiceEli Lilly and Co. John Lechleiter, Ph.D.EMD Serono Howard Mayer, M.D.Euro RSCG Life Catapult Jeffrey Hoffmanevoke interaction B. Reid ConnollyExelixis Fran HellerFlaum Idea Group Sander FlaumFrestedt Inc. Joy FrestedtGeoVax Inc. Harriet Robinson, Ph.D.GlaxoSmithKline Alex LancksweertGlaxoSmithKline Philip Priest GlaxoSmithKline Darielle RudermanGSW Worldwide Joseph DaleyHarrison and Star Tyrone CurranHealthcare Regional

Marketing Scott WeintraubHealogix Harris KaplanHistogen Gail Naughton, Ph.D.Hospira Inc. Sumant

Ramachandra, M.D., Ph.D.i3 Gregg DearhammerICON Clinical Research Bill TaaffeIDEA Pharma Mike ReaINC Research Javier Revuelta Pérez, Ph.D. Inclinix Linda Goldman

Infinity Pharmaceuticals Julian Adams, Ph.D.Johnson & Johnson Lars MerkKendle Stephen Cutler, Ph.D.MCS Healthcare

Public Relations Calep A. (Joe) Boyd IIIMediciGlobal Duncan ShawMedidata Solutions Andrew NewbiggingMedimix International Henry GazayMedImmune Tristan Vaughan, Ph.D.MedImmune Gail Wasserman, Ph.D.MicroMass Communications Alyson ConnorMillennium: The Takeda

Oncology Company Joseph Bolen, Ph.D.Molecular Profiles Ltd. Nikin PatelNovartis Joe JimenezNovartis AG Kim StrattonOceana Therapeutics Inc. David Tierney, M.D.Ogilvy CommonHealth

Medical Marketing Darlene DobryOnyx Pharmaceuticals N. Anthony Coles, M.D.Palio Uwe Tigör, M.D.The Patient Recruiting

Agency Lance NickensPDR Network Edward Fotsch, M.D.Pennsylvania

Biotechnology Center Timothy Block, Ph.D. Pfizer Inc. Freda Lewis-Hall, M.D.PharmaLink Inc. Ahsan AwanPHT Corp. Philip LeePPD Henrietta Ukwu, M.D. Prism Ideas James Sawyer, MBChBPublicis Touchpoint

Solutions Rick KeeferPurdue Pharma LP Mitchell Katz, Ph.D.Qforma Roger Jones, Ph.D.QualityHealth Robert RebakQuintiles Inc. Amir Kalali, M.D.RCW McCann Healthcare Jeff SweeneyRoska Healthcare

Advertising Kurt MuellerSanofi Dennis UrbaniakSanofi Christopher ViehbacherSeaside Therapeutics Randall Carpenter, M.D. Shire Human Genetic

Therapies Sylvie Grégoire, Pharm.D.The Snow Companies Nadine McGowanThe Snow Companies Michael SimoneSpaulding Clinical Yolanda DavisStiefel, a GSK company William HumphriesSunovion Pharmaceuticals Nobuhiko TamuraSynergistix Don SchenkerTeva Women’s Health Keeshia MuhammadTGaS Advisors James MercanteTorre Lazur Healthcare

Group Mark WillmannUnited BioSource Corp. Annette Stemhagen, Dr.PHVeeva Vault Jennifer GoldsmithVertex Pharmaceuticals Fredrick Van Goor, Ph.D.

Who’s on the List — 2011 Indexed by Company Affiliation

3PharmaVOICE � July/August 2011

4 July/August 2011 � PharmaVOICE

worked relentlessly for two years to secure$39.6 million in Series A funding for the com-pany and a second tranche of $14.5 million Se-ries A funding last December. He has been in-strumental in the company’s 16 patentapplications and overseeing the company’s leadprogram in Type 2 diabetes. This program isadvancing to the clinic rapidly — the mole-cule was synthesized in December 2008 andwill be in the clinic later this year, only twoand a half years from idea to dosing in humans. Dr. Jirousek realized he had chosen the

right career many years ago when a compoundhe co-invented was first dosed in patients, andhe saw the results of that clinical trial and thedifference he could make on patient’s lives. Dr. Jirousek holds patient benefit above other

motivators in the industry. While it is importantto show activity of a new and exciting drug can-didate, he cautions others to temper interpreta-tions until the safety profile is also known. Thislevel of maturity in thinking is an inspiration toothers to be objective in their thought processesregarding new drug discovery. PV

ment of inflammatory and metabolic diseases.Colleagues say Dr. Jirousek has a unique andhighly valued skill set and he is well-knownin the metabolic disease field in both academ-ics and the pharmaceutical industry. A chemist by trade, Dr. Jirousek has a big

picture view of drug discovery and developmentand has a deep understanding and knowledge ofbiology, pharmacology, and medicine.Throughout his career, Dr. Jirousek has been re-sponsible for co-inventing and/or bringing 12compounds from inception to the clinical pro-gression of potential new therapeutics to treatcancer, obesity, diabetes, and diabetic complica-tions. One of these compounds is Arxxant, aninvestigational drug being developed by Lillyfor diabetic peripheral retinopathy.Within the community, Dr. Jirousek sits

on the NIH and SBIR grant committees. Hehas also organized and run metabolic meet-ings for the pharmaceutical/biotech industry.Dr. Jirousek constantly encourages every-

one around him to think outside of the box.He stimulates innovation and creativity, anddoes not accept that something cannot bedone. He is relentlessly passionate about hiswork, viewing his profession of making med-icines not as a job, but rather a mission. Dr. Jirousek’s contribution to the industry

will come from the Catabasis platform andtechnology, which he was a driving force tohelp invent. He helped fund Catabasisthrough the economic downturn in 2008, and

In 2008, Michael Jirousek, Ph.D., co-founded Catabasis Pharmaceuticals, a bio-pharmaceutical company focused on leverag-ing the therapeutic potential of omega-3 fattyacids and other clinically validated com-pounds to create new medicines for the treat-

CURIOUS. ENERGETIC.NAME: Michael R. Jirousek, Ph.D.

CURRENT POSITION: Co-founder and Chief Science Officer,Catabasis Pharmaceuticals

DATE AND PLACE OF BIRTH: December 1958; Cleveland, Ohio

EDUCATION: B.S., Kent State University; Ph.D., Case WesternReserve University; Post-doctoral fellowship, Harvard University

FIRST JOB: Park ranger in junior high school

FIRST INDUSTRY-RELATED JOB: Consultant, AmericanCyanamid

ALTERNATIVE PROFESSION: Professor of chemical biology

PROFESSIONAL MENTORS: Professor Yoshito Kishi, HarvardUniversity; Robert Solomon, Case Western Reserve University

PROFESSIONAL ASSOCIATIONS: American Chemical Society;American Association for the Advancement of Science;American Diabetes Association; European Association forthe Study of Diabetes; The Endocrine Society

GIVING BACK: Juvenile Diabetes Research Foundation

CONNECTED VIA: LinkedIn

WORDS TO LIVE BY: If it is to be, it is up to me

Dr. MichaelJirousek is

poised to changethe direction of treatment for

inflammatory andmetabolic diseases.

Michael R. JIROUSEK, Ph.D.taking a new sCientifiC approaCh

Dr. Michael Jirousek is an

avid runner, who likes to

participate in marathons. ?DID YOU KNOW?

Entrepreneurs

Mike Jirousek, Ph.D., impresses all hemeets and is comfortable interacting

with key opinion leaders in the field, Nobellaureates, members of scientific advisoryboards, scientists, and so on. As co-founder and chief science officer of

Catabasis Pharmaceuticals, he enjoys debatingscientific theories, the plausibility of scientificplans, as well as experiments, especially whenit comes to his company’s pipeline of products.He is providing an important influence on

the life-sciences industry as a whole and has asuccessful track record in both big pharma andbiotech companies. He has already made sig-nificant contributions to the discovery of newmolecules that may ultimately prove to be ef-ficacious in treating obesity and diabetes. Dr.Jirousek’s work has been on the cutting-edgeof new science, particularly at Sirtris, where he

was previous to co-founding Catabasis. The molecules that he has designed and, in

some cases, has personally synthesized, havebeen important agents in the elucidation of bi-ological processes. If Catabasis is successful, industry experts say

it will be used as a case study for how to start abiotech company. Dr. Jirousek and his co-founder Jill Milne, Ph.D., and CEO, haveworked hard for almost two years without sig-nificant funding and moved their ideas along soimpressively that they were able to secure almost$40 million to get Catabasis rolling in earnest. Their early results are so compelling that ex-

perts say their work will revolutionize the treat-ment of type 2 diabetes. Mr. Jirousek’s work atCatabasis may, in fact, provide a new platform ofcompounds to treat a variety of inflammatoryconditions beyond diabetes. PV

FAMILY: Son, Mike Jr.

HOBBIES: Running

READING LIST: Born to Run

FAVORITE BOOKS: Outliers by Malcolm Gladwell andThe Art of Peace by Morihei Ueshiba

FAVORITE MOVIE: Braveheart

BUCKET LIST: Cure a disease

INSPIRED BY: Patients who need the new medicineshe is working to discover and develop

FAVORITE SMARTPHONE APP: Good Reader

MOST UNUSUAL PLACE VISITED: Egypt

LIFE LESSONS: Whatever you do, do it wholeheartedly

UNDER THE CLOAK OF INVISIBILITY: Observe the NobelAssembly discussing the selection of the nextNobel laureates

TIME TRAVEL: Back to 1831 to travel on the HMS Beagle with Charles Darwin through the GalapagosIslands

!Getting Personal withDR. MICHAEL JIROUSEKCatalyst for Change